| Literature DB >> 34579006 |
Peter E Levanovich1, Charles S Chung1, Dragana Komnenov2, Noreen F Rossi1,2,3.
Abstract
Fructose and salt intake remain high, particularly in adolescents and young adults. The present studies were designed to evaluate the impact of high fructose and/or salt during pre- and early adolescence on salt sensitivity, blood pressure, arterial compliance, and left ventricular (LV) function in maturity. Male 5-week-old Sprague Dawley rats were studied over three 3-week phases (Phases I, II, and III). Two reference groups received either 20% glucose + 0.4% NaCl (GCS-GCS) or 20% fructose + 4% NaCl (FHS-FHS) throughout this study. The two test groups ingested fructose + 0.4% NaCl (FCS) or FHS during Phase I, then GCS in Phase II, and were then challenged with 20% glucose + 4% NaCl (GHS) in Phase III: FCS-GHS and FHS-GHS, respectively. Compared with GCS-GCS, systolic and mean pressures were significantly higher at the end of Phase III in all groups fed fructose during Phase I. Aortic pulse wave velocity (PWV) was elevated at the end of Phase I in FHS-GHS and FHS-FHS (vs. GCS-GCS). At the end of Phase III, PWV and renal resistive index were higher in FHS-GHS and FHS-FHS vs. GCS-GCS. Diastolic, but not systolic, LV function was impaired in the FHS-GHS and FHS-FHS but not FCS-FHS rats. Consumption of 20% fructose by male rats during adolescence results in salt-sensitive hypertension in maturity. When ingested with a high-salt diet during this early plastic phase, dietary fructose also predisposes to vascular stiffening and LV diastolic dysfunction in later life.Entities:
Keywords: aortic stiffness; fructose; glucose; hypertension; left ventricular diastolic dysfunction; pulse wave velocity; renal resistive index
Mesh:
Substances:
Year: 2021 PMID: 34579006 PMCID: PMC8465679 DOI: 10.3390/nu13093129
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Schematic of the Timeline of Experimental Protocols and Study Phases. Rat age and study week are depicted across the timeline. R, recovery period; A, acclimation to metabolic cages; B, baseline. Surgery for telemetry transmitter placement and ultrasound studies are as indicated. Groups are subsequently depicted by their sugar-salt intake in Phases I and III.
Initial and Final Body Weights, Heart Weights, Glycemic Parameters and Plasma Renin Activity among the Four Groups of Rats.
| Dietary Regimen |
| Initial Weight | Final Weight (g) | Heart Weight (g/kg) | Fasting Glucose | Fasting | G:I Ratio (×106) | PRA |
|---|---|---|---|---|---|---|---|---|
|
| 9 | 125 ± 4 | 381 ± 9 | 3.3 ± 0.1 | 128 ± 13 | 1.14 ± 0.23 | 64.7 ± 6.4 | 1.82 ± 0.20 |
|
| 9 | 132 ± 4 | 347 ± 10 | 3.4 ± 0.1 | 129 ± 24 | 0.74 ± 0.12 | 74.6 ± 12.6 | 0.66 ± 0.12 * |
|
| 8 | 128 ± 3 | 362 ± 12 | 3.2 ± 0.1 | 126 ± 14 | 1.33 ± 0.12 | 31.6 ± 1.9 *,† | 1.35 ± 0.28 |
|
| 9 | 127 ± 5 | 366 ± 12 | 3.4 ± 0.1 | 118 ± 11 | 1.03 ± 0.17 | 39.1 ± 7.1 † | 1.09 ± 0.29 |
GCS-GCS, 20% glucose + 0.4% NaCl in Phases I–III; FCS-GHS, 20% fructose + 0.4% NaCl in Phase 1 and 20% glucose +4% NaCl in Phase III; FHS-GHS, 20% fructose + 4% NaCl in Phase 1 and 20% glucose + 4% NaCl in Phase III; FHS-FHS, 20% fructose + 4% NaCl in Phases I–III. PRA, plasma renin activity; G:I Ratio, glucose:insulin ratio. All groups except FHS-FHS were on 20% glucose + 0.4% NaCl in Phase II. Due to lack of sufficient plasma for insulin, n values for insulin and G:I Ratio are as follows: 5, 6, 7 and 7. Values are the mean ± SE; n as indicated per group. * p < 0.05 vs. GCS-GCS. † p < 0.05 vs. FCS-GHS.
Daily Caloric and Sodium Consumption.
|
| |||||||
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
| 9 | 61.5 ± 1.7 | 3.0 ± 0.3 | 68.4 ± 1.3 | 3.0 ± 0.1 | 66.0 ± 2.1 | 2.9 ± 0.1 |
|
| 9 | 60.7 ± 2.6 | 2.7 ± 0.1 | 67.2 ± 1.4 | 3.0 ± 0.1 | 65.7 ± 2.0 | 3.2 ± 0.3 |
|
| 8 | 48.7 ± 1.6 *,† | 23.5 ± 0.8 *,† | 60.6 ± 2.2 * | 29.2 ± 1.1 *,† | 61.8 ± 2.1 | 29.3 ± 0.9 *,† |
|
| 9 | 51.9 ± 2.1 *,† | 24.9 ± 1.0 *,† | 63.9 ± 1.2 | 30.9 ± 0.6 *,† | 63.5 ± 1.5 | 31.0 ± 0.8 *,† |
|
| |||||||
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
|
| 9 | 62.6 ± 1.9 | 2.8 ± 0.1 | 63.5 ± 2.1 | 2.9 ± 0.1 | 64.3 ± 1.8 | 2.8 ± 0.1 |
|
| 9 | 45.9 ± 1.7 * | 22.1 ± 0.8 * | 54.4 ± 1.4 * | 26.2 ± 0.7 * | 57.1 ± 1.3 | 27.5 ± 0.6 * |
|
| 8 | 50.1 ± 2.5 * | 23.3 ± 1.2 * | 56.1 ± 2.2 | 26.0 ± 0.8 * | 59.9 ± 2.0 | 27.7 ± 0.6 * |
|
| 9 | 60.5 ± 1.6 †,§ | 27.5 ± 0.8 * | 63.9 ± 1.9 †,§ | 29.0 ± 0.3 * | 66.4 ± 2.6 † | 29.9 ± 1.0 * |
Values are the mean ± SE, n as indicated per group. Group names as in Table 1. Caloric intake calculated using caloric profiles of 3.98 kcal/g and 3.61 kcal/g for 0.4% and 4% NaCl chow, respectively. * p < 0.05 vs. GCS-GCS; † p < 0.05 vs. FCS-GHS; § p < 0.05 vs. FHS-GHS.
Hemodynamic Parameters in the Four Groups of Rats at Baseline and End of Phase 1 and Phase 3.
| ( | ||||||
|
|
| |||||
|
|
|
|
|
| ||
|
| 9 | 100.0 ± 1.0 | 108.4 ± 1.6 | 465 ± 8 | 391 ± 16 | |
|
| 9 | 100.7 ± 0.9 | 108.0 ± 0.9 | 458 ± 9 | 395 ± 15 | |
|
| 8 | 100.6 ± 1.3 | 111.1 ± 1.3 | 456 ± 11 | 381 ± 8 | |
|
| 9 | 99.4 ± 1.0 | 110.2 ± 1.4 | 451 ± 11 | 391 ± 11 | |
| ( | ||||||
|
|
|
|
|
|
|
|
|
| 7 | 10 ± 1.0 | 11 ± 2.2 | 11 ± 1.2 | −92 ± 11 | 2.4 ± 1.5 |
|
| 8 | 15 ± 0.9 * | 18 ± 0.9 * | 14 ± 1.3 | −103 ± 18 | 4.2 ± 1.6 |
|
| 8 | 15 ± 1.4 * | 18 ± 1.7 * | 13 ± 1.7 | −105 ± 6 | 4.2 ± 2.0 |
|
| 8 | 16 ± 2.0 ** | 19 ± 2.3 ** | 14 ± 1.9 | −89 ± 14 | 4.6 ± 1.4 |
Group names as in Table 1. Values are the mean ± SE, n as indicated per group. (A) Mean arterial pressure (MAP) and heart rate (HR) at baseline and at the end of Phase I. (B) Study-wide changes in hemodynamics calculated as the difference between measurements taken at the end of Phase III and baseline values at the beginning of Phase I. Values are the mean ± SE, n as indicated per group. * p < 0.05 vs. GCS-GCS; ** p < 0.01 vs. GCS-GCS.
Figure 2Pulse Wave Velocity at the end of Phases I and III. Pulse wave velocity (PWV) of the ascending aorta assessed (A) at the end of Phase I and (B) at the end of Phase III. Group labels are as described in the legend for Table 1. Values are the mean ± SE; n as depicted on the graphs. * p < 0.05 vs. GCS-GCS (by one-way ANOVA); † p < 0.05 vs. FHS-FHS in Phase I (by two-way ANOVA with repeated measures).
Figure 3Renal Resistive Index at the end of Phases I and III. Renal resistive index (RRI) of the left main renal artery using doppler imaging (A) at the end of Phase I and (B) at the end of Phase III. Values are the mean ± SE; n as depicted on the graphs. * p < 0.05 vs. GCS-GCS in Phase III.
Echocardiographic Parameters at the End of Phase III.
| Groups | ||||
|---|---|---|---|---|
| GCS-GCS | FCS-GHS | FHS-GHS | FHS-FHS | |
|
| 9 | 8 | 8 | 9 |
|
| 74.9 ± 3.4 | 77.3 ± 4.4 | 80.3 ± 3.7 | 78.2 ± 2.3 |
|
| 46.0 ± 3.4 | 49.1 ± 4.4 | 51.9 ± 4.4 | 48.8 ± 2.4 |
|
| 3.7 ± 0.3 | 3.4 ± 0.4 | 3.0 ± 0.4 | 3.5 ± 0.3 |
|
| 6.7 ± 0.3 | 6.5 ± 0.3 | 6.1 ± 0.4 | 6.9 ± 0.4 |
|
| 3.2 ± 0.1 | 3.3 ± 0.2 | 3.5 ± 0.2 | 3.6 ± 0.1 |
|
| 1.9 ± 0.03 | 2.0 ± 0.1 | 2.5 ± 0.1 * | 2.2 ± 0.1 * |
|
| 3.5 ± 0.1 | 3.5 ± 0.2 | 4.0 ± 0.3 | 4.0 ± 0.2 |
|
| 2.3 ± 0.1 | 2.4 ± 0.1 | 3.0 ± 0.3 * | 2.7 ± 0.2 |
|
| 6.8 ± 0.2 | 6.8 ± 0.4 | 7.4 ± 0.3 | 7.6 ± 0.4 |
|
| 4.3 ± 0.1 | 4.4 ± 0.2 | 5.6 ± 0.4 * | 4.9 ± 0.3 |
|
| 1190 ± 73 | 1060 ± 59 | 1401 ± 56 * | 1373.0 ± 75 * |
Group names as in Table 1: LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening; LVIDs, left ventricular systolic internal diameter; LVIDD, left ventricular diastolic internal diameter; LVAW, left ventricular anterior wall width; LVPW, left ventricular posterior wall width; LVTW, left ventricular total wall width; LV Mass, left ventricular mass. Values are the mean ± SE. * p < 0.05 vs. GCS-GCS.
Figure 4Assessment of Left Ventricular Parameters in Phase III. Images were acquired using a short axis view of the left ventricle (LV) via M-Mode. (A) Cardiac mass was the total wet weight of the heart after harvesting. (B) Total wall thickness was the sum of anterior and posterior LV wall widths. (C) LV diastolic diameter was the diameter of the LV at end diastole. (D) LV diastolic wall/diameter was calculated as the ratio of total wall thickness to the diameter of the LV at end-diastole. Values are the mean ± SE, n as indicated per group; * p < 0.05 vs. GCS-GCS. (E) Representative histological sections of LV tissue from each group. Group labels are as described in the legend for Table 1. Mason’s trichrome; 40× magnification.
Figure 5Assessment of Diastolic Function. (A) Representative Doppler images of transmitral flow patterns from GCS-GCS and FHS-FHS rats at the end of Phase III. (B) Ratio of early (E-wave) to late (A-wave) left ventricular filling (E-wave) left ventricular filling as index of diastolic function. Group labels are as described in the legend for Table 1. Values are the mean ± SE; n as indicated per group, * p < 0.05 vs. GCS-GCS.
Echocardiographic Parameters Associated with Diastolic Function at the End of Phase III.
| Group | ||||
|---|---|---|---|---|
| GCS-GCS | FCS-GHS | FHS-GHS | FHS-FHS | |
|
| 9 | 8 | 8 | 9 |
|
| 706 ± 22 | 630 ± 45 | 652 ± 41 | 641 ± 39 |
|
| 555 ± 27 | 550 ± 44 | 576 ± 34 | 621 ± 32 |
|
| 1.31 ± 0.06 | 1.16 ± 0.06 | 1.14 ± 0.06 | 1.03 ± 0.04 ** |
|
| 39.5 ± 4.0 | 28.0 ± 2.2 * | 31.8 ± 3.0 | 25.4 ± 2.3 ** |
|
| 25.5 ± 1.0 | 27.7 ± 1.5 | 27.6 ± 1.1 | 29.0 ± 0.9 |
|
| 34.1 ± 2.6 | 32.3 ± 4.6 | 34.2 ± 4.0 | 27.4 ± 1.8 |
|
| 45.3 ± 3.7 | 45.8 ± 4.7 | 48.0 ± 4.9 | 47.1 ± 4.7 |
|
| 22.5 ± 1.9 | 25.2 ± 6.2 | 21.1 ± 3.3 | 24.3 ± 2.3 |
|
| 0.81 ± 0.01 | 0.71 ± 0.09 | 0.81 ± 0.15 | 0.64 ± 0.01 |
Group names as in Table 1: E, early phase ventricular filling; A, late phase ventricular filling; DT, mitral valve deceleration time; IVRT, isovolumetric relaxation time; E’, mitral annulus early phase filling; A’, mitral annulus late phase filling. Values are the mean ± SE. * p < 0.05 vs. GCS-GCS, ** p < 0.01 vs. GCS-GCS.